The Drug Repurposing Hub: a next-generation drug library and information resource
- PMID: 28388612
- PMCID: PMC5568558
- DOI: 10.1038/nm.4306
The Drug Repurposing Hub: a next-generation drug library and information resource
Conflict of interest statement
The authors declare no competing financial interests.
Figures


Similar articles
-
DrugR+: A comprehensive relational database for drug repurposing, combination therapy, and replacement therapy.Comput Biol Med. 2019 Jun;109:254-262. doi: 10.1016/j.compbiomed.2019.05.006. Epub 2019 May 8. Comput Biol Med. 2019. PMID: 31096089
-
Drug databases and their contributions to drug repurposing.Genomics. 2020 Mar;112(2):1087-1095. doi: 10.1016/j.ygeno.2019.06.021. Epub 2019 Jun 18. Genomics. 2020. PMID: 31226485 Review.
-
DrugMap Central: an on-line query and visualization tool to facilitate drug repositioning studies.Bioinformatics. 2013 Jul 15;29(14):1834-6. doi: 10.1093/bioinformatics/btt279. Epub 2013 May 15. Bioinformatics. 2013. PMID: 23681121 Free PMC article.
-
Expanding the scope of drug repurposing in pediatrics: the Children's Pharmacy Collaborative.Drug Discov Today. 2014 Nov;19(11):1696-1698. doi: 10.1016/j.drudis.2014.08.003. Epub 2014 Aug 19. Drug Discov Today. 2014. PMID: 25149597 Free PMC article.
-
Web-based drug repurposing tools: a survey.Brief Bioinform. 2019 Jan 18;20(1):299-316. doi: 10.1093/bib/bbx125. Brief Bioinform. 2019. PMID: 29028878 Review.
Cited by
-
Worldwide analysis of actionable genomic alterations in lung cancer and targeted pharmacogenomic strategies.Heliyon. 2024 Sep 5;10(17):e37488. doi: 10.1016/j.heliyon.2024.e37488. eCollection 2024 Sep 15. Heliyon. 2024. PMID: 39296198 Free PMC article.
-
An In Vitro Investigation of the Antiproliferative and Antimetastatic Effects of Levosimendan: Potential Drug Repurposing for Cervical Cancer.Curr Issues Mol Biol. 2024 Jun 27;46(7):6566-6579. doi: 10.3390/cimb46070391. Curr Issues Mol Biol. 2024. PMID: 39057033 Free PMC article.
-
IL10RB as a key regulator of COVID-19 host susceptibility and severity.medRxiv [Preprint]. 2021 Jun 2:2021.05.31.21254851. doi: 10.1101/2021.05.31.21254851. medRxiv. 2021. Update in: NPJ Genom Med. 2022 Sep 5;7(1):52. doi: 10.1038/s41525-022-00324-x. PMID: 34100031 Free PMC article. Updated. Preprint.
-
Strategies to Enhance Logic Modeling-Based Cell Line-Specific Drug Synergy Prediction.Front Physiol. 2020 Jul 28;11:862. doi: 10.3389/fphys.2020.00862. eCollection 2020. Front Physiol. 2020. PMID: 32848834 Free PMC article.
-
A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic.bioRxiv [Preprint]. 2020 Jun 30:2020.06.30.180380. doi: 10.1101/2020.06.30.180380. bioRxiv. 2020. Update in: Cell Rep Med. 2020 Oct 29;1(8):100137. doi: 10.1016/j.xcrm.2020.100137. PMID: 32637960 Free PMC article. Updated. Preprint.
References
-
- Nosengo N. Can you teach old drugs new tricks? Nature. 2016;534:314–316. - PubMed
-
- Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40–51. - PubMed
-
- Goldstein I, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998;338:1397–1404. - PubMed
-
- Palumbo A, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111:3968–3977. - PubMed
-
- Lamb J, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929–1935. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical